SCHEMBL3260266

SCHEMBL3260266

NC(=O)C=CC1CCNCC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.38
GABRA1 P14867 2/20 0.38
GABRG2 P18507 2/20 0.38
GABRB3 P28472 2/20 0.38
GABRA5 P31644 2/20 0.38
GABRA3 P34903 2/20 0.38
GABRA2 P47869 2/20 0.38
GABRA6 Q16445 2/20 0.38
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38
GABRB1 P18505 1/20 0.38
GABRB2 P47870 1/20 0.38
GABRA4 P48169 1/20 0.38
GABRE P78334 1/20 0.38
PMP22 Q01453 1/20 0.38
GABRG1 Q8N1C3 1/20 0.38
GABRG3 Q99928 1/20 0.38
GABRQ Q9UN88 1/20 0.38
NOS2 P35228 1/20 0.37
EPHX1 P07099 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3260263 1.00 TSHR (0.38) TSHRGABRA1GABRG2GABRB3GABRA5
Acetic Acid SCHEMBL27798837 0.92 GABRP (0.38) TSHRGABRA1GABRG2GABRB3GABRA5
SCHEMBL543403 0.84
SCHEMBL730203 0.84 HDAC2 (0.34) TSHR
SCHEMBL21001913 0.80 TSHR (0.44) TSHRGABRA1GABRG2GABRB3GABRA5
SCHEMBL4743867 0.79
SCHEMBL532572 0.79 GRIN1 (0.39) EPHX1
Hydrochloric Acid SCHEMBL422775 0.78 TSHR (0.43) TSHRGABRA1GABRG2GABRB3GABRA5
Hydrochloric Acid SCHEMBL422774 0.78 TSHR (0.43) TSHRGABRA1GABRG2GABRB3GABRA5
SCHEMBL4079497 0.77 GRIN1 (0.41) EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100048633-A1 Piperidine-4-acrylamides LEHR PHILIPP 2010-02-25 US disclosed
US-20100048633-A1 Piperidine-4-acrylamides LEHR PHILIPP 2010-02-25 US disclosed
CN-101600693-A The piperidin-acetamide derivatives that is used for the treatment of inflammatory or anaphylactic disease NOVARTIS AG (CH) 2009-12-09 CN disclosed
EP-2125731-A1 PIPERIDIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC DISEASES Novartis AG (CH) 2009-12-02 EP disclosed
WO-2008092844-A1 PIPERIDIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC DISEASES NOVARTIS AG (CH) 2008-08-07 WO disclosed
WO-2006071035-A1 NOVEL ([1,3]THIAZOLO[5,4-B]PYRIDIN-2-YL)-2-CARBOXAMIDE DERIVATIVES LG LIFE SCIENCES, LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048633-A1 Piperidine-4-acrylamides CCR3, CCR1, CCR4 TSHR 2900/4885GABRA1 1814/4885GABRG2 1387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.